There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics Inc (VYGR) and Helius Medical Technologies (HSDT) with bullish sentiments.
Voyager Therapeutics Inc (VYGR)
Cantor Fitzgerald analyst Charles Duncan initiated coverage with a Buy rating on Voyager Therapeutics Inc today and set a price target of $27. The company’s shares opened today at $18.12.
Duncan said:
“. We are initiating coverage of VYGR with an Overweight rating and 12-month PT of $27. Voyager is developing innovative gene-therapy- based drug candidates for several debilitating CNS diseases that we believe could prove transformational. The company’s platform for engineering AAV vectors enables targeted gene delivery to the CNS along with sustained expression, enabling one-time treatments that may result in disease course-modifying activity. The platform has recently generated not one, but two, signed partnerships in 2019, that we believe provide external validation of the technical & clinical potential of underlying candidates.”
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 2.3% and a 48.6% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Strong Buy with an average price target of $23.13, implying a 27.6% upside from current levels. In a report issued on February 22, Robert W. Baird also reiterated a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Helius Medical Technologies (HSDT)
Helius Medical Technologies received a Buy rating and a $10 price target from Oppenheimer analyst Steven Lichtman today. The company’s shares opened today at $7.05, close to its 52-week low of $6.69.
Lichtman wrote:
“We are initiating coverage of HSDT with an Outperform rating and a $10 price target. Stimulator (PoNS) device is used in conjunction with physical therapy to activate brain healing. Its initial target market is patients with balance deficit disabilities due to mild-to-moderate traumatic brain injury (mTBI). While FDA approval is still pending and market development work remains, the opportunity ahead is significant: an estimated 2.1M people in the US suffer from chronic symptoms of TBI with a primary complication of balance or gait disability. 2019 represents a key year for Helius as it awaits FDA approval and begins a rollout in Canada. Pilot studies have been completed in additional large indications.”
According to TipRanks.com, Lichtman has 0 stars on 0-5 star ranking scale with an average return of -4.8% and a 50.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care Inc, Boston Scientific Corp, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Helius Medical Technologies with a $12 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
